Channel our experience into patient trust
Since 1994, Biologics has worked closely with biopharma partners, providers and payers to support patients on complex medication therapies. Our 98% patient satisfaction rate reflects the difference our specialty pharmacy support makes.
When cost is a challenge, our team connects patients with grants or other financial assistance programs that may reduce out-of-pocket costs. Before treatment begins, pharmacists help patients understand what to expect, and once therapy starts, nurses provide ongoing guidance to help patients manage side effects and continue therapy as prescribed.
Specialty pharmacy capabilities at a glance
As an independent specialty pharmacy, Biologics by McKesson adds value across the specialty journey as part of the extended care team. We combine reliable dispensing with focused knowledge of disease states and advanced therapies. Our pharmacists and registered nurses help patients navigate challenging care journeys, while our access teams support providers through specialty prescription processes, prior authorizations, appeals and more.
30 +
Years of specialty pharmacy experience
200 +
Cancer and rare disease therapies
100 +
Oral therapies, including oral oncolytics
130 +
Limited distribution medications
30,000 +
Active provider relationships
500 +
Contracted payer networks
98 %
Patient satisfaction
Who benefits from Biologics specialty services?
From help with costs to managing side effects, Biologics supports patients, caregivers and their families through every step of care.
Our specialty expertise goes beyond dispensing medication to help patients start and stay on therapy.
Biopharma Partners
We support commercialization and access, including pharmacy and medical billing expertise, across the specialty lifecycle for oncology, rare and orphan diseases, and cell and gene therapies, supported by hub services.
Our 500+ payer contracts help plan sponsors provide cost-effective specialty medication access and strong clinical support for their members.
Biologics by McKesson is proud to offer more than 200 therapies that represent the leading edge of specialty treatment for cancer and rare and complex diseases.
Explore our specialty capabilities
Biologics works with complex therapies, including exclusive and limited-distribution drugs. We support nearly every part of the specialty journey.
Oncology
Biologics was the nation’s first cancer-focused specialty pharmacy partner. Today, we bring personalized support to high-volume therapies.
Rare and orphan disease
Our exclusive disease- and therapy-aligned teams set us apart. These teams receive deep training on diseases, therapies and patient populations, including children and teens.
Cell & gene therapy
We offer pharmacy and hub services for high-risk cell and gene therapies. McKesson’s InspiroGene™ center of excellence brings it all together.
Hub services
Our patient hubs are purpose-built with our biopharma partners. Together, we help deliver the brand’s vision for patient care.
Patient access
The high cost of specialty medications can keep patients from starting or continuing therapy. We connect them with programs to help.
Provider support
Time to therapy matters, and so does staying on treatment. Biologics works with provider offices beyond the dispense, supporting patients throughout treatment and keeping care teams informed along the way.
Explore how we can support your therapy’s journey from launch and beyond.
News & Stories
Biologics Drug Launches
Effective July 13, Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner.
Effective July 7, Cycle Pharmaceuticals’ PHYRAGO™ (dasatinib) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner
Biologics by McKesson became the exclusive specialty pharmacy provider for DECNUPAZ, an intravenous therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm.
Biologics by McKesson became the exclusive specialty pharmacy provider for ZYCUBO, the first FDA-approved treatment for pediatric patients with Menkes disease.
Biologics by McKesson’s Pharmacy Elite was selected as Rigel’s hub for Tavalisse, Gavreto, and Rezlidhia, supporting access services including benefits investigation, prior authorization, and financial assistance navigation.
Biologics by McKesson became the sole specialty pharmacy provider for AQVESME, indicated for adults with non-transfusion-dependent or transfusion-dependent alpha- or beta-thalassemia.
Biologics by McKesson was selected as a limited specialty pharmacy provider for Komzifti, an oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
Biologics by McKesson was selected as a limited specialty pharmacy provider for Inluriyo, an oral estrogen receptor antagonist for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer.
Biologics by McKesson was selected as a limited specialty pharmacy provider for PALSONIFY, the first once-daily oral therapy for adults with acromegaly who need an alternative to surgery.
Biologics by McKesson, in partnership with InspiroGene by McKesson, was chosen as the exclusive specialty pharmacy for a newly approved immunotherapy for adults with recurrent respiratory papillomatosis.
Biologics by McKesson, in partnership with InspiroGene, supports Amtagvi, the first FDA-approved one-time cell therapy for a solid tumor in patients with unresectable or metastatic melanoma.
Biologics by McKesson was selected as a limited specialty pharmacy provider for WAYRILZ, an oral BTK inhibitor for adults with persistent or chronic immune thrombocytopenia.
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.